Status:
COMPLETED
Study to Investigate Effect of a New Drug (PF-00446687) in Males Suffering From Erectile Dysfunction
Lead Sponsor:
Pfizer
Conditions:
Erectile Dysfunction
Eligibility:
MALE
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate the effect of up to 200 mg of PF-00446687 on erectile activity in males suffering from erectile dysfunction as well as examining the safety and toleration o...
Eligibility Criteria
Inclusion
- Males aged 18-65 years who has given written informed consent to participate in the study and who suffers moderate to severe erectile dysfunction who has a current or recent successful response to treatment with phosphodiesterase type 5 inhibitors
Exclusion
- Males with a history of significant cardiac disease; unstable angina or recent myocardial infarction.
- Males suffering from treated or untreated hypo- or hypertension
- Males currently receiving vasoactive medication
- Males taking medications contraindicated, or cautioned with sildenafil or MC4 agonists
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00862888
Start Date
July 1 2007
End Date
February 1 2008
Last Update
April 8 2009
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Oslo, Norway
2
Pfizer Investigational Site
Belfast, Northern Ireland, United Kingdom, BT9 6AD
3
Pfizer Investigational Site
Leeds, WEST Yorkshire, United Kingdom, LS2 9LH